<DOC>
	<DOCNO>NCT01816464</DOCNO>
	<brief_summary>The overall aim project evaluate immunogenicity TIV vaccination HIV-uninfected pregnant woman compare HIV-uninfected non-pregnant woman 2013 . Safety data also collected.THe Pregnancy outcome transplacental transfer antibody also assess .</brief_summary>
	<brief_title>Immunogenicity Safety Trivalent Influenza Vaccine Pregnant Nonpregnant HIV Uninfected Women</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All woman ( ) Documented HIV1 uninfected one assay use Prevention Mother Child Transmission ( PMTCT ) / program undertaken within 12 week study enrolment . ( ii ) Able understand comply plan study procedure . ( iii ) Provides write informed consent prior initiation study . ( iv ) Women age ≥ 18 year &lt; 39 year . pregnant woman ( ) Gestational age ≥20 week &lt; 36 week document approximate date last menstrual period corroborate physical exam sonar report available . All woman ( ) Receipt TIV , study , current influenza season document medical history record . ( ii ) Receipt live license vaccine ≤ 28 day vaccine ( except tetanus toxoid vaccine ) ≤ 14 day prior studyvaccine . ( iii ) Receipt nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) ≤ 28 day prior vaccination study , expect receive another nonlicensed agent delivery unless study approval obtain . ( iv ) Any significant ( opinion site investigator ) acute illness and/or oral temperature great equal 38 degree C ≤ 24 hour prior study entry . ( v ) Use anticancer systemic chemotherapy radiation therapy ≤ 48 week study enrollment , immunosuppression result underlie illness treatment . ( vi ) Long term use glucocorticoid , include oral parenteral prednisone ≥ 20 mg/day equivalent 2 consecutive week ( 2 week total ) ≤ 12 week study entry , highdose inhaled steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) ≤ 12 week study entry ( nasal topical steroid allow ) . ( vii ) Receipt immunoglobulin blood product ( exception Rho D immune globulin ) ≤ 12 week prior enrollment study schedule receive immunoglobulin blood product ( exception Rho D immune globulin ) pregnancy first 24 week delivery . ( viii ) Receipt immune mediator ≤ 12 week enrollment . ( ix ) Uncontrolled major psychiatric disorder . ( x ) History severe adverse reaction previous TIV . ( xi ) Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . pregnant woman ( ) Receipt corticosteroid preterm labor ≤ 14 day study entry . ( ii ) Pregnancy complication ( current pregnancy ) preterm labor , hypertension ( Blood Pressure ( BP ) &gt; 140/90 presence proteinuria BP &gt; 150/100 , without proteinuria currently antihypertensive medication ) preeclampsia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccination</keyword>
</DOC>